Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Drugs in R&D · 2024
DOI: 10.1007/s40268-024-00490-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drugs in R&D, 2024. Verfasst von Shan Jing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zai Lab.
Abstract (Originalsprache)
BACKGROUND: Efgartigimod, a human immunoglobulin G (IgG)1-derived Fc fragment targeting the neonatal Fc receptor, has been developed into intravenous (IV) and subcutaneous (SC) formulations for treating generalized myasthenia gravis (gMG) and other autoimmune diseases. Data in the Chinese population were not available to date, and while both formulations have been approved in the USA, the EU, Japan and China for the treatment of gMG. OBJECTIVE: We present the pharmacokinetic, pharmacodynamic, and safety of IV and SC PH20 efgartigimod in healthy Chinese participants. METHODS: In two independent, double-blinded, placebo-controlled, phase I studies of the IV and SC formulations of efgartigimod, healthy Chinese adults were randomized 3:1 to receive active treatment or matching placebo once every 7 days for four doses. Primary endpoints were pharmacokinetic parameters. RESULTS: After the fourth IV infusion, a mean maximum observed concentration (Cmax) of 194 µg/mL was reached at the end of the 1 h infusion; the mean area under concentration-time curve from time zero to 168 h (AUC0-168h) was 5300 µg × h/mL. After the fourth SC injection, a mean Cmax of 42.1 µg/mL was achieved with a median Tmax of 47.74 h; the mean AUC0-168h was 4790 µg × h/mL. Maximal mean reductions from baseline in total IgG levels were reached approximately 24 days after the first dose (60.7%, IV formulation; 66.4%, SC formulation). Treatment-related adverse events (TRAEs) were reported in seven (58.3%) participants receiving SC efgartigimod, mostly injection-site reactions. No TRAEs or AEs of special interest were reported in the IV study. CONCLUSIONS: The efgartigimod IV and SC pharmacokinetic, pharmacodynamic, and safety profiles in Chinese participants were similar to the known profiles in non-Chinese participants. Both formulations effectively reduced total IgG levels by a similar percentage. CLINICAL TRIAL REGISTRATION: CTR20211952 and CTR20211805.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Zai Lab (Shanghai) Co., Ltd, Shanghai, China.
- argenx, Ghent, Belgium.
- Curare Consulting B.V., Liempde, the Netherlands.
- Zai Lab (US) LLC, Cambridge, MA, USA.
Förderung
- Zai Lab
Zitieren
APA
Jing, S., Zhang, Y., Lin, Y., Gu, X., Liu, J., Guglietta, A., Noukens, J., Van Bragt, T., Wang, L., Chen, J., Reinhart, H., & Pu, X. (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. Drugs in R&D. https://doi.org/10.1007/s40268-024-00490-6
Vancouver
Jing S, Zhang Y, Lin Y, Gu X, Liu J, Guglietta A, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. Drugs in R&D. 2024. doi:10.1007/s40268-024-00490-6
BibTeX
@article{Jing2024,
author = {Jing, Shan and Zhang, Yu and Lin, Yang and Gu, Xiaowen and Liu, Jing and Guglietta, Antonio and Noukens, Jan and Van Bragt, Tonke and Wang, Lina and Chen, Jiajia and Reinhart, Harald and Pu, Xia},
title = {Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants},
journal = {Drugs in R&D},
year = {2024},
doi = {10.1007/s40268-024-00490-6}
}
EUVIMED